Skip to content

    Gland Pharma Limited

    GLANDNeutral
    Healthcare·3 Feb 2025
    Management Summary

    Gland Pharma delivered a resilient Q3 FY25, characterized by significant margin expansion in its base business despite a revenue decline in that segment. While the consolidated performance was bolstered by new launches and improved product mix, the Cenexi acquisition continues to face operational and regulatory headwinds, delaying its EBITDA breakeven target. Management is pivoting towards high-value biologics and CDMO opportunities to drive long-term growth.

    Highlights

    7
    • Consolidated Revenue stood at ₹1,384.1 crore (INR 13,841 million), with a consolidated EBITDA margin of 26%, up 300 bps YoY.

    • Base business (ex-Cenexi) EBITDA margin reached a robust 39%, compared to 34% in the same period last year.

    • Net Profit (PAT) increased by 7% YoY to ₹204.7 crore (INR 2,047 million), showing a 25% sequential growth.

    • Cenexi reported a negative EBITDA of ₹31.2 crore (INR 312 million) due to an unannounced regulatory inspection at the Fontenay site.

    • Launched 13 new molecules in the US market during the quarter, strengthening the product portfolio.

    • Received EIR from the US FDA for Dundigal and Pashamylaram facilities, signifying successful closure of inspections.

    • Signed a CDMO collaboration term sheet with Shanghai Henlius Biotech for biosimilar manufacturing.

    Concerns

    1
    • Regulatory Inspection Impact at Cenexi

    What Changed2

    vs Q4 FY25

    Tone shiftGood → NeutralGuidance items6 → 5 (-1)

    Key financials

    Single quarter

    05 metrics
    1. 01Revenue13,841 Mn
    2. 02EBITDA Margin26%
    3. 03PAT2,047 Mn+7.0%YoY
    4. 04R&D Spend437 Mn-17.5%YoY
    5. 05Base Business EBITDA Margin39%

    Segment breakdown

    Base Business (ex-Cenexi)
    10,123 Mn Revenue39% EBITDA Margin-8% Revenue Growth
    Cenexi
    41 Mn Revenue-312 Mn EBITDA77% Gross Margin
    List

    Guidance & targets

    5
    CategoryTargetPriority
    Profitability
    Cenexi EBITDA Breakeven
    Q3 FY26
    Medium
    Revenue
    Cenexi Annual Revenue Threshold
    €200 million
    Medium
    Revenue
    Biologics CDMO Revenue Generation
    Incremental revenue
    High
    Capacity
    Biologics Drug Substance Capacity Expansion
    15 KL
    Medium
    Capex
    GLP-1 Cartridge Capacity Investment
    ₹200 crore
    Medium

    Risks & concerns

    5
    RiskSeverity

    Regulatory Inspection Impact at Cenexi

    Unannounced ANSM inspection at Fontenay facility halted production for 3 weeks and requires corrective measures, delaying profitability.Management acknowledged

    high

    Dependency on Chinese API for Heparin

    Management admits continued dependence on China for Heparin API, though they view potential US tariffs on Chinese finished products as a competitive advantage.Both acknowledged

    medium

    US Market Volume Volatility

    Analysts questioned the Q-o-Q decline in US run rate; management attributed it to shipping timing for Enoxaparin and Ketorolac.Analyst downplayed

    medium

    Areas of Evasion(2)

    • Specific details on the observations from the ANSM inspection at Cenexi.
    • Exact revenue numbers for the GLP-1 contracts.

    Q&A highlights

    3

    “It is just a shipping timing thing which instead of Q3, we will be probably planning for next quarter.”

    Clarifies that the 8% revenue drop in the base business was due to timing of shipments (Enoxaparin) rather than structural demand issues.

    asked by Bino Pathiparampil, Elara Capital

    2 min read5 chapters

    Detailed Narrative

    01

    Cenexi Regulatory Headwinds Delay Profitability

    The Cenexi business recorded revenue of €41 million in Q3 FY25, which was below management's internal estimates. The primary driver for this miss was an unannounced inspection by the French Health Authority (ANSM) at the Fontenay facility, which disrupted manufacturing for approximately three weeks. Consequently, the timeline for EBITDA breakeven has been pushed back from Q4 FY25 to Q3 FY26. Management is now focused on pushing annual revenue beyond the €200 million threshold to achieve sustainable profitability.

    02

    Base Business Margin Resilience Amidst Volume Shifts

    Gland's base business (excluding Cenexi) demonstrated strong operational efficiency, with EBITDA margins expanding to 39% from 34% YoY. This improvement occurred despite an 8% YoY revenue decline in the segment, which management attributed to shipping delays for key products like Enoxaparin and Ketorolac. The margin expansion was driven by a favorable product mix, including 13 new molecule launches in the US, and effective cost management measures.

    03

    Strategic Pivot to Biologics and CDMO

    Management highlighted two major collaborations in the biologics space: a partnership with Dr. Reddy's Laboratories and a new non-binding term sheet with Shanghai Henlius Biotech. To support these initiatives, Gland is evaluating a significant capacity expansion of 15 KL in drug substance manufacturing, with an estimated capex of $80 million to $100 million. Incremental revenue from the Dr. Reddy's collaboration is expected to begin in FY26.

    04

    US Market Dynamics and Regulatory Clearance

    The company received a major regulatory boost with the receipt of EIRs for its Dundigal and Pashamylaram facilities, successfully closing large-scale US FDA inspections. In the US market, Gland launched 27 molecules and 39 SKUs year-to-date, with new launches contributing approximately 5% of total revenue in Q3. Management remains aggressive in the US, targeting complex generics and RTU (Ready-to-Use) infusion bags to maintain high gross margins.

    05

    Geographic Diversification and RoW Strategy

    Revenue from Rest of the World (RoW) markets increased to 21% of total revenues. Under the new CEO, Shyamakant Giri, Gland is shifting its RoW strategy from a 'continent lens' to focusing on top-tier high-value countries like Saudi Arabia, Mexico, and South Africa. While a Saudi tender shipment was delayed this quarter, management expects allotment to hospitals to resume in Q4 FY25 or early FY26.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.